Bayer AG (XTER:BAYN) FFO


XTER:BAYN Bayer AG XTER:BAYN
62 GF Score
Price €39.59
GF Value €27.37
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Bayer AG FFO?

FFO (Funds from operations) only applies to REITs.

XTER:BAYN
62GF Score
Bayer AG XTER:BAYN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bayer AG (XTER:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of €39.59 is trading 44.6% above its estimated GF Value™ of €27.37. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XTER:BAYN:

  • FFO:
  • GF Value™: €27.37 vs. price of €39.59 (44.6% above fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the XTER:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
62GF Score

Get the complete analysis for XTER:BAYN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€39.59
Price
€27.37
GF Value